Stock RVU RYVU THERAPEUTICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ryvu Therapeutics S.A.

Equities

RVU

PLSELVT00013

Delayed Warsaw S.E.
Other stock markets
 05:28:57 2024-04-30 am EDT 		5-day change 1st Jan Change
48.7 PLN -0.31% Intraday chart for Ryvu Therapeutics S.A. -4.13% -15.30%
Mar. 13 Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 06 Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
RYVU THERAPEUTICS S.A. Stock Ryvu Therapeutics S.A.
-15.30% 280M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.63% 102B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.62% 96.29B
B+
ARGENX SE Stock argenx SE
+1.69% 22.18B
B
BIONTECH SE Stock BioNTech SE
-16.67% 21.2B
B+
GENMAB A/S Stock Genmab A/S
-8.70% 18.31B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 17.38B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.41% 13.97B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.57% 12.17B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. RVU Stock
  4. Ratings Ryvu Therapeutics S.A.